Inspira Receives First Ever Purchase Order for INSPIRA ART100 Systems in U.S. First units expected to be shipped in Q4 2024. The Purchase Order follows the recent FDA Clearance of the INSPIRA ART100. Ra'anana, Israel

Receives First Ever Purchase Order for INSPIRA ART100 Systems in U.S.

First units expected to be shipped in Q4 2024.

The Purchase Order follows the recent FDA Clearance of the INSPIRA ART100.

Ra'anana, Israel, June 13, 2024 -

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a breakthrough

medical technology company, today announced that is has received the first purchase order from Glo-Med Networks, Inc. ("Glo-Med")

for its INSPIRA ART100 systems, with the five product units expected to be shipped in the fourth quarter of 2024. The purchase

order also provides for the potential purchase of an additional 20 systems, the timing of which is subject to further agreement between

Inspira and Glo-Med.

The planned shipment and potential additional sales of the INSPIRA

ART100 systems is a pivotal step in the Company's growth model, which is primarily based on the INSPIRA ART (Gen 2) that

is currently in development and is expected to target the $19 billion mechanical ventilator market, with its next generation cutting-edge

technology designed to replace the need for mechanical ventilation. The Company plans to offer hospitals receiving the INSPIRA

ART100 an option with special terms for the integrated HYLA Blood Sensor and INSPIRA ART (Gen 2) devices, subject to the

completion of the development of those products, which are also subject to approval by regulatory entities.

Joe Hayon, Director, President and co-founder of Inspira stated: "We

continue to develop the breakthrough technologies of tomorrow. The INSPIRA ART100, is our first and important step in building

the INSPIRA market presence and position in preparation for the INSPIRA ART (Gen 2), which we believe has the potential to provide

a new clinical solution with a potentially different intent of use for the mega life support and mechanical ventilation market."

The Company already began the commercial manufacturing of the INSPIRA

ART100 with the first five units planned for shipment to Glo-Med, a distributor for Inspira products in the U.S., with the devices planned

for deployment in U.S. hospitals.

About Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company

in the life support arena. The INSPIRA ART (Gen 2), also known as the INSPIRA ART500, shall include the Company's Adaptive

Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed

oxygen volume straight into the blood. By elevating patient oxygen saturation levels in minutes, this technology potentially allows patients

to remain awake during treatment and therefore may enable patients to be treated in and beyond intensive care units, reducing the need

for mechanical ventilation systems that requires intubation and medically induced coma.

The Company received FDA 510(k) clearance for its INSPIRA ART100, a

Cardiopulmonary Bypass System.

The Company's other products, including the INSPIRA ART (Gen 2) and

HYLA blood sensor, have not yet been tested or used in humans and have not been approved by any regulatory entity.

For more information, please visit our corporate website: https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements

pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations

of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it

discusses the expected timing of the delivery of the INSPIRA ART100 systems, the potential for future orders, the belief that the

planned shipment and potential additional sales of INSPIRA ART100 systems is a pivotal step in the Company's growth model,

that it expects its INSPIRA ART100 systems to be deployed in U.S. hospitals and that it began the commercial manufacturing of the

INSPIRA ART100 with the first five units planned for shipment to U.S. hospitals. These forward-looking statements and their implications

are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties

that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required

by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or

circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and

uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on

Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"),

which is available on the SEC's website, http://www.sec.gov

Public Relations Manager

Inspira Technologies

Copyright 2018-2024 Inspira Technologies OXY B.H.N. LTD., All